May 14, 2018 Clinical Research/Diagn. Life Science Tools PR/Corporate

Precipio Announces Preliminary Q1 2018 Year-Over-Year Revenue Increase of 286%

Growth resulting from commercial team reorganization, product and service cross-selling, and increased business stabilization NEW HAVEN, Conn., May 14, 2018 (GLOBE NEWSWIRE) — Specialty diagnostics company Precipio, Inc. (NASDAQ:PRPO), announces preliminary, unaudited 1st quarter 2018 revenues of approximately $712,000, representing a 286% increase from the same quarter in the prior year. Drivers of revenue growth that have been... Read more

April 11, 2018 Clinical Research/Diagn. Life Science Tools

Precipio Launches ICE COLD-PCR(TM) Research Access Program for Cancer Centers

COMPLIMENTARY PRECIPIO ICE COLD PCR™  KITS NOW AVAILABLE TO ADVANCE BODY OF RESEARCH AND ACCELERATE MARKET EXPANSION NEW HAVEN, Conn., April 11, 2018 (GLOBE NEWSWIRE) — Specialty diagnostics company Precipio, Inc. (NASDAQ:PRPO), announced today the launch of its program to provide complimentary ICE COLD-PCR (ICP) kits to cancer researchers studying the field of liquid biopsy. The program... Read more

March 22, 2018 Clinical Research/Diagn. PR/Corporate

Precipio Restructures Capitalization Table

INVESTORS TO CONVERT PREFERRED SHARES AND EXERCISE WARRANTS NEW HAVEN, Conn., March 22, 2018 (GLOBE NEWSWIRE) — Specialty diagnostics company Precipio, Inc. (NASDAQ:PRPO), in an 8-K issued today announced an agreement with investors in certain 2017 underwritten and registered direct offerings, to convert their preferred shares and exercise a substantial portion of their warrants. The benefit to common stockholders... Read more

March 13, 2018 Licensing, IP, and Legal

Precipio Settles Lawsuit With Crede Capital

COMPLETES RESTRUCTURING OF CLOSE TO 95% TRANSGENOMIC LIABILITIES NEW HAVEN, Conn., March 13, 2018 (GLOBE NEWSWIRE) — Specialty diagnostics company Precipio, Inc. (NASDAQ:PRPO), announced today it has settled its lawsuit with Crede Capital Group LLC, restructuring the final substantial liability of legacy payables inherited as part of the merger with Transgenomic in June 2017. These... Read more

January 16, 2018 Life Science Tools PR/Corporate

PRECIPIO APPOINTS NEW SALES VP TO MANAGE DIAGNOSTICS SALES EXPANSION

SALES GROWTH ACCELERATION PLAN TO TRIPLE SIZE OF ONCOLOGIST/HOSPITAL SALES TEAM IN 2018 NEW HAVEN, Conn., Jan. 16, 2018 (GLOBE NEWSWIRE) — Specialty diagnostics firm Precipio, Inc. (NASDAQ:PRPO) has appointed Douglas Sites to the new position of Vice President of Sales where he will be responsible for executing Precipio’s Pathology Services sales plan, targeting oncologists... Read more

December 20, 2017 Life Science Tools Product Launch

PRECIPIO LAUNCHES ITS SECOND NEW ICE-COLD PCR(TM) TARGETED ENRICHMENT KIT TO IDENTIFY MUTATIONS IN LUNG CANCER USING LIQUID (BLOOD) BIOPSIES ON SANGER SEQUENCING PLATFORMS

NEW HAVEN, Conn., Dec. 20, 2017 (GLOBE NEWSWIRE) — Precipio, Inc. (NASDAQ:PRPO), announced today the launch of the second new version of its ICE-COLD PCR™ (ICP) enrichment kit, used to identify resistance mutations in non-small cell lung cancer (NSCLC) using liquid biopsies. As part of the transformation of ICP to be platform-agnostic, this kit has... Read more

June 16, 2017 M&A, Partnerships PR/Corporate

PRECIPIO AND TRANSGENOMIC ANNOUNCE EXPERTS FROM YALE AND HARVARD JOINING NEW SCIENTIFIC ADVISORY BOARD TO SUPPORT MERGED COMPANY’S GROWTH INITIATIVES

Distinguished Experts in Disease Diagnosis and Diagnostics Technology Bring World Class Scientific Acumen and Insight to Help Guide the New Merged Company’s Expansion and Growth Other Recent Pre-Merger Developments Include EPO Decision to Grant Patent Protection in Europe for Transgenomic’s Multiplexed ICE COLD-PCR and Completion of Reverse Stock Split NEW HAVEN, Conn. and OMAHA, Neb.,... Read more